vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and HACKETT GROUP, INC. (HCKT). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($70.9M vs $68.8M, roughly 1.0× HACKETT GROUP, INC.). HACKETT GROUP, INC. runs the higher net margin — 6.2% vs 4.7%, a 1.5% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs -11.6%). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (28.1% CAGR vs -5.9%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Hackett Limited is a British multi-channel retailer of clothing for men and boys, with a broad range of apparel and accessories. It was founded in 1983 in London, England. As of June 2019, the company had 160 stores globally, with its flagship store at 14 Savile Row in London. It is owned by both Lebanese holding company M1 Group and American L Capital Asia
ADPT vs HCKT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $70.9M | $68.8M |
| Net Profit | $3.4M | $4.3M |
| Gross Margin | 73.6% | 70.8% |
| Operating Margin | -27.1% | 13.0% |
| Net Margin | 4.7% | 6.2% |
| Revenue YoY | 35.1% | -11.6% |
| Net Profit YoY | — | 36.2% |
| EPS (diluted) | — | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $70.9M | $68.8M | ||
| Q4 25 | $71.7M | $75.8M | ||
| Q3 25 | $94.0M | $73.1M | ||
| Q2 25 | $58.9M | $78.9M | ||
| Q1 25 | $52.4M | $77.9M | ||
| Q4 24 | $47.5M | $79.2M | ||
| Q3 24 | $46.4M | $79.8M | ||
| Q2 24 | $43.2M | $77.7M |
| Q1 26 | $3.4M | $4.3M | ||
| Q4 25 | $-13.6M | $5.6M | ||
| Q3 25 | $9.5M | $2.5M | ||
| Q2 25 | $-25.6M | $1.7M | ||
| Q1 25 | $-29.9M | $3.1M | ||
| Q4 24 | $-33.7M | $3.6M | ||
| Q3 24 | $-32.1M | $8.6M | ||
| Q2 24 | $-46.2M | $8.7M |
| Q1 26 | 73.6% | 70.8% | ||
| Q4 25 | 74.6% | 41.7% | ||
| Q3 25 | 80.7% | 40.7% | ||
| Q2 25 | 69.4% | 35.4% | ||
| Q1 25 | 67.6% | 35.8% | ||
| Q4 24 | 62.0% | 39.4% | ||
| Q3 24 | 64.1% | 29.2% | ||
| Q2 24 | 55.3% | 27.5% |
| Q1 26 | -27.1% | 13.0% | ||
| Q4 25 | -17.8% | 12.0% | ||
| Q3 25 | 10.9% | 7.5% | ||
| Q2 25 | -42.5% | 5.8% | ||
| Q1 25 | -56.4% | 5.7% | ||
| Q4 24 | -71.3% | 9.8% | ||
| Q3 24 | -70.3% | 16.0% | ||
| Q2 24 | -109.6% | 16.1% |
| Q1 26 | 4.7% | 6.2% | ||
| Q4 25 | -18.9% | 7.4% | ||
| Q3 25 | 10.2% | 3.5% | ||
| Q2 25 | -43.5% | 2.1% | ||
| Q1 25 | -56.9% | 4.0% | ||
| Q4 24 | -71.0% | 4.5% | ||
| Q3 24 | -69.1% | 10.8% | ||
| Q2 24 | -107.0% | 11.3% |
| Q1 26 | — | $0.17 | ||
| Q4 25 | $-0.08 | $0.20 | ||
| Q3 25 | $0.06 | $0.09 | ||
| Q2 25 | $-0.17 | $0.06 | ||
| Q1 25 | $-0.20 | $0.11 | ||
| Q4 24 | $-0.22 | $0.11 | ||
| Q3 24 | $-0.22 | $0.31 | ||
| Q2 24 | $-0.31 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.6M | — |
| Total DebtLower is stronger | — | $78.8M |
| Stockholders' EquityBook value | — | $66.0M |
| Total Assets | $505.9M | $204.4M |
| Debt / EquityLower = less leverage | — | 1.19× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.6M | — | ||
| Q4 25 | $70.5M | $18.2M | ||
| Q3 25 | $55.0M | $13.9M | ||
| Q2 25 | $43.2M | $10.1M | ||
| Q1 25 | $50.6M | $9.2M | ||
| Q4 24 | $47.9M | $16.4M | ||
| Q3 24 | $38.1M | $10.0M | ||
| Q2 24 | $59.8M | $19.1M |
| Q1 26 | — | $78.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $66.0M | ||
| Q4 25 | $218.8M | $68.1M | ||
| Q3 25 | $204.4M | $101.6M | ||
| Q2 25 | $179.7M | $119.8M | ||
| Q1 25 | $190.4M | $114.4M | ||
| Q4 24 | $202.7M | $115.6M | ||
| Q3 24 | $223.8M | $110.9M | ||
| Q2 24 | $241.6M | $102.2M |
| Q1 26 | $505.9M | $204.4M | ||
| Q4 25 | $512.7M | $206.4M | ||
| Q3 25 | $490.6M | $200.7M | ||
| Q2 25 | $496.6M | $200.5M | ||
| Q1 25 | $510.9M | $191.8M | ||
| Q4 24 | $539.4M | $193.3M | ||
| Q3 24 | $558.5M | $190.8M | ||
| Q2 24 | $584.9M | $187.5M |
| Q1 26 | — | 1.19× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
Segment breakdown not available.
HCKT
| Revenue before reimbursements | $36.4M | 53% |
| Other | $32.0M | 47% |
| Reimbursements | $405.0K | 1% |
